A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Name: A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Published: 2024
License: Public Domain

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

chronic myeloid leukemia, chronic phase, chronic myeloid leukemia, allosteric inhibitor of bcr-abl1, cml, tern-701, t315i, t315i mutant, cardinal, hs-10382, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Related documents